Update Series (2020) Lesson 20: Management of Asymptomatic Renal Calculi and Residual Fragments

NOTE: CME is no longer available for this activity.

Now in its 39th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed in consultation with and edited by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. 

Target Audience

  • Urologist
  • Resident

Learning Objectives

At the conclusion of this continuing medical education activity, the participant will be able to describe the prevalence of asymptomatic de novo and post-procedural urinary calculi, and identify the risk factors associated with stone/fragment progression and outcomes of observation versus treatment.

Course summary
Course opens: 
06/01/2020
Course expires: 
06/30/2033
Price:
$99.00
Rating: 
0

David F. Friedlander, MD, MPH

Disclosures: Nothing to disclose

 

Garrick M. Greear, MD

Disclosures: Nothing to disclose

 

and

 

Roger L. Sur, MD

Disclosures: Boston Scientific, Retrophin: Consultant/Advisor; Cook Medical, Karl Storz: Meeting Participant/Lecturer; Kalera Medical, Inc.: Leadership Position

 

Department of Urology

University of California San Diego Health System

San Diego, California

NOTE: CME is no longer available for this activity.

This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.
 
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest.The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Disclosures
Individual authors’ disclosures are located with their articles in each issue of The Update Series.

Update Series Advisory Group

NameCompanyRole
Benjamin Newell Breyer, MD, FACSWorld Journal UrologyHealth Publishing
Sexual Medicine Open AccessHealth Publishing
Shelby EnglertNothing to disclose 
E. Ann Gormley, MDACGMELeadership Position
ABMSLeadership Position
AUA UpdatesLeadership Position
Cheryl Taylore Lee, MDmerckConsultant or Advisor
Mel RiteScientific Study or Trial
Brian Matlaga, MD, MPHBoston ScientificConsultant or Advisor
David Christopher Miller, MD, MPHBlue Cross Blue Shield of MichiganOther
National Cancer InstituteScientific Study or Trial
John Patrick Mulhall, MDAssociation of Peyronie's Disease Advocates (APDA)Leadership Position
sexual medicine society of north americaLeadership Position
the journal of sexual medicineLeadership Position
vaultConsultant or Advisor
Curtis Nickel, MDFarr LaboratoriesConsultant or Advisor
AUAHealth Publishing
NIHScientific Study or Trial
Canadian Institute of Health ResearchScientific Study or Trial
Alvio TherapeuticsConsultant or Advisor
Seikagaku CorporationConsultant or Advisor
RedLeaf MedicalScientific Study or Trial
TEVAConsultant or Advisor
Craig Stuart Niederberger, MDAMERICAN SOCIETY FOR REPRODUCTIVE MEDICINELeadership Position
NexHandLeadership Position
Ferring PharmaceuticalsScientific Study or Trial
Core outcomes measure for infertility trials (COMMIT)Consultant or Advisor
Victor William Nitti, MDAstellasHealth Publishing,
AllerganHealth Publishing
Serenity PharmeuticalsInvestment Interest
MedtronicScientific Study or Trial
AmphoraScientific Study or Trial
J. Kellogg Parsons, MD, MHSMDx HealthConsultant or Advisor
DendronConsultant or Advisor
Boston ScientificConsultant or Advisor
Eila Curlee Skinner, MDGenentechScientific Study or Trial
Stacy T. Tanaka, MDAUA Update SeriesHealth Publishing
Journal of UrologyHealth Publishing
Centers for Disease Control and Prevention (CDC)Scientific Study or Trial
American Board of UrologyOther
American Academy of Pediatrics, Section on UrologyLeadership Position
J. Christian Winters, MDStimGuardConsultant or Advisor


Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
 
Reproduction Permission: Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.
 
Peer Review: Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Advisory Board.

Released date: June 2020
Expiration date: June 2023

Price

Price:
$99.00
Please login or register to take this course.